These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 17915392)

  • 41. FDA tightens its grip on drug regulation.
    Coombes R
    BMJ; 2007 Feb; 334(7588):290-1. PubMed ID: 17289729
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The case for preemption of prescription drug failure-to-warn claims.
    Kim CH
    Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
    [No Abstract]   [Full Text] [Related]  

  • 44. Contaminated dietary supplements.
    Carvajal R
    N Engl J Med; 2010 Jan; 362(3):274; author reply 274. PubMed ID: 20089984
    [No Abstract]   [Full Text] [Related]  

  • 45. Trends in boxed warnings and withdrawals for novel therapeutic drugs, 1996 through 2012.
    Cheng CM; Shin J; Guglielmo BJ
    JAMA Intern Med; 2014 Oct; 174(10):1704-5. PubMed ID: 25127107
    [No Abstract]   [Full Text] [Related]  

  • 46. Medical device reporting: issues with Class III medical devices.
    Zigler J; Walsh J; Zigler J
    Food Drug Law J; 2007; 62(3):573-80. PubMed ID: 17915398
    [No Abstract]   [Full Text] [Related]  

  • 47. Reform of drug regulation--beyond an independent drug-safety board.
    Ray WA; Stein CM
    N Engl J Med; 2006 Jan; 354(2):194-201. PubMed ID: 16407517
    [No Abstract]   [Full Text] [Related]  

  • 48. The Food and Drug Administration's regulation of risk disclosure for implantable cardioverter defibrillators: has technology outpaced the Agency's regulatory framework?
    Basile EM; Lorell BH
    Food Drug Law J; 2006; 61(2):251-72. PubMed ID: 16903031
    [No Abstract]   [Full Text] [Related]  

  • 49. Assessing the safety and comparative effectiveness of follow-on biologics (biosimilars) in the United States.
    Hennessy S; Leonard CE; Platt R
    Clin Pharmacol Ther; 2010 Feb; 87(2):157-9. PubMed ID: 20107450
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FDA embraces risk-management approach.
    Fox JL
    Nat Biotechnol; 2003 Oct; 21(10):1120-1. PubMed ID: 14520383
    [No Abstract]   [Full Text] [Related]  

  • 51. Has the FDA Amendments Act of 2007 impaired drug development?
    Franson TR
    Clin Pharmacol Ther; 2011 Feb; 89(2):169-71. PubMed ID: 21252933
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sporicidin responds to the recall of its products.
    Healthc Hazard Mater Manage; 1992 Aug; 5(11):8-11. PubMed ID: 10121070
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Civil and criminal liability associated with food recalls.
    Packman JM
    Food Drug Law J; 1998; 53(3):437-52. PubMed ID: 10346721
    [No Abstract]   [Full Text] [Related]  

  • 54. Pharmaceuticals: drug importation--2005. End of Year Issue Brief.
    Varma P; Seay M
    Issue Brief Health Policy Track Serv; 2005 Dec; ():1-20. PubMed ID: 16708457
    [No Abstract]   [Full Text] [Related]  

  • 55. FDA seeks to clear up confusion about compounding.
    J Am Vet Med Assoc; 2003 Oct; 223(8):1103, 1106. PubMed ID: 14584731
    [No Abstract]   [Full Text] [Related]  

  • 56. The rise and fall of Natrecor for congestive heart failure: implications for drug policy.
    Kesselheim AS; Fischer MA; Avorn J
    Health Aff (Millwood); 2006; 25(4):1095-102. PubMed ID: 16835191
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Medical devices post-approval studies program: vision, strategies, challenges and opportunities.
    Marinac-Dabic D; Bonhomme M; Loyo-Berrios N; Gross T; Ciperson R; Gardner S; Marcarelli M
    Food Drug Law J; 2007; 62(3):597-604. PubMed ID: 17915402
    [No Abstract]   [Full Text] [Related]  

  • 58. Pharmacy compounding of bioidentical hormone replacement therapy (BHRT): a proposed new approach to justify FDA regulation of these prescription drugs.
    Patsner B
    Food Drug Law J; 2008; 63(2):459-91. PubMed ID: 18561473
    [No Abstract]   [Full Text] [Related]  

  • 59. Drug product liability and health care delivery systems.
    Sage WM
    Stanford Law Rev; 1988 Apr; 40(4):989-1026. PubMed ID: 10318110
    [No Abstract]   [Full Text] [Related]  

  • 60. The cosmetic/drug dilemma: FDA regulation of alpha-hydroxy acids.
    Heymann LA
    Food Drug Law J; 1997; 52(4):357-75. PubMed ID: 10346670
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.